arrow
P

Peter Ettmayer

boehringer ingelheim austria
H指数:45
被引数:8,141

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Identification of a Highly Cooperative PROTAC Degrader Targeting GTP-Loaded KRAS(On) Alleles

鉴定一种靶向结合GTP的KRAS(On)等位基因的高度协同作用的PROTAC降解剂

2025-10-300
OAAI
Targeting cancer with small-molecule pan-KRAS degraders

用小分子pan-kras降解剂靶向癌症

Science
IF45.8
2024-01-010
OA
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling

发现对HER2外显子20插入驱动的肿瘤有效的和选择性的HER2抑制剂,其保留野生型EGFR信号传导

2022-07-2615
PRE
opnMe.com: a digital initiative for sharing tools with the biomedical research community

opnMe.com: 与生物医学研究社区共享工具的数字倡议

2022-04-2218
OA
One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS

一个原子就能改变一切: 在SOS1和KRAS之间进门

2021-03-1540
PRE
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition

BI-3406是一种有效的选择性SOS1-KRAS相互作用抑制剂,通过联合MEK抑制对KRAS驱动的癌症有效

2021-01-06276
OAAI
BI-3406 and BI 1701963: Potent and selective SOS1::KRAS inhibitors induce regressions in combination with MEK inhibitors or irinotecan

BI-3406和BI 1701963: 有效和选择性的SOS1::KRAS抑制剂与MEK抑制剂或伊立替康联合诱导消退

2020-08-1530
PRE
Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance

选择性和有效的CDK8/19抑制剂增强NK细胞活性并促进肿瘤监测

2020-04-0245
OAAI
Discovery of BI-3406: A potent and selective SOS1::KRAS inhibitor opens a new approach for treating KRAS-driven tumors
2019-12-016
PRE
Effective targeting of KRAS-driven tumors by the first-in-class, orally bioavailable SOS1::KRAS inhibitor BI-3406
2019-12-012
PRE
Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors
2019-11-05117
OAAI
Intracellular Trapping of the Selective Phosphoglycerate Dehydrogenase (PHGDH) Inhibitor BI-4924 Disrupts Serine Biosynthesis
2019-07-3151
PREAI
BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design (vol 15, pg 672, 2019)
2019-07-0211
OAAI
Structure-based PROTAC design demonstrates BAF complex ATPase vulnerabilities in cancer
2019-07-011
PRE
Selective and potent CDK8 inhibitors enhance NK cell activity and promote tumor surveillance
2019-07-010
PRE
BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
2019-06-10381
OAAI
Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions
2019-02-09106
OAAI
Chemically induced degradation of the transcription factor BCL6
2018-07-010
PRE